Meyka Pro banner
Bristol-Myers Squibb Company Ce

Bristol-Myers Squibb Company Ce (CELG-RI) Stock Competitors & Peer Comparison

See (CELG-RI) competitors and their performances in Stock Market.

CELG-RINYSE
HealthcareDrug Manufacturers - General
$0.10
$0.00(0.00%)
U.S. Market opens in 17h 17m

Peer Comparison Table: Drug Manufacturers - General Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
CELG-RI$0.10-7.50%204MN/AN/AN/A
LLY$1,146.85-2.74%1.1T38.98$29.42+0.56%
JNJ$248.82-1.67%599B23.19$10.73+2.10%
ABBV$253.38-0.44%447.8B24.87$10.19+2.70%
MRK$124.41-2.42%307.3B22.74$5.47+2.69%
NVS$149.56-2.73%285.3B17.21$8.69+3.16%
NVO$49.61-1.41%220.6B12.32$4.03+3.63%
AMGN$364.17-0.58%196.5B16.48$22.10+2.69%
GILD$133.21-0.80%165.4B15.92$8.37+2.42%
PFE$24.75-1.20%141B8.09$3.06+6.95%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

CELG-RI vs LLY Comparison July 2026

CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CELG-RI stands at 204M. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, CELG-RI is priced at $0.10, while LLY trades at $1,146.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CELG-RI currently has a P/E ratio of N/A, whereas LLY's P/E ratio is 38.98. In terms of profitability, CELG-RI's ROE is N/A, compared to LLY's ROE of +1.01%. Regarding short-term risk, CELG-RI is more volatile compared to LLY. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.Check LLY's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions